Drug shortages homepage

Welcome to Drug Shortages Canada, the website for reporting drug shortages and discontinuations in Canada. The Food and Drug Regulations require drug sellers to report when they are not able to meet demand for a product or when they stop selling a product. Information about the website and the regulations can be found on the About & Resources Page.

A shortage means, in respect of a drug, a situation in which the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug is unable to meet the demand for the drug.

A discontinuation means, in respect of a drug, a situation in which the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug, permanently ceases the sale of the drug.

Tier 3 drug shortages are those that have the greatest potential impact on Canada's drug supply and health care system. Impact is based on low availability of alternative supplies, ingredients or therapies. The Tier Assignment Committee (TAC), composed of federal and provincial/territorial governments, healthcare professionals, and industry stakeholders, makes recommendations on the tier assignment of drug shortages. The TAC assessment includes:

  • a review of the information gathered on the shortage issue, and
  • a thorough discussion on its potential impact and next steps.

Below are the newest and most recently updated Shortage and Discontinuation reports. Alternatively, please visit the Tier 3 page to see current Tier 3 Drug Shortages and associated shortage or discontinuation reports.

Drug pills

LEGEND

!!T3 denotes an actual Tier 3 shortage/discontinuation

!T3 denotes an anticipated Tier 3 shortage/discontinuation

Shortage Reports

Brand name Company Name Status Strength Update Date Updated View Report
APO-DASATINIB APOTEX INC Actual shortage 70MG Updated Report 2022-08-11 164882
AVALIDE SANOFI-AVENTIS CANADA INC Resolved 12.5MG 300MG Updated Report 2022-08-11 166530
AVALIDE SANOFI-AVENTIS CANADA INC Avoided shortage 12.5MG 300MG Updated Report 2022-08-11 158890
EZETIMIBE SIVEM PHARMACEUTICALS ULC Actual shortage 10MG New Report 2022-08-11 166524
SUMATRIPTAN DF SIVEM PHARMACEUTICALS ULC Actual shortage 50MG New Report 2022-08-11 166521
PLAVIX SANOFI-AVENTIS CANADA INC Actual shortage 75MG Updated Report 2022-08-11 165000
GLUCOPHAGE SANOFI-AVENTIS CANADA INC Actual shortage 500MG Updated Report 2022-08-11 165003
FERRLECIT SANOFI-AVENTIS CANADA INC Actual shortage 12.5MG Updated Report 2022-08-11 164234
ALOXI ELVIUM LIFE SCIENCES Actual shortage 0.5MG Updated Report 2022-08-11 163388
DANTRIUM INTRAVENOUS ENDO PAR INNOVATION COMPANY, LLC Actual shortage 20MG Updated Report 2022-08-11 166508

Discontinuation Reports

Brand name Company Name Status Strength Update Date Updated View Report
HEPTOVIR GLAXOSMITHKLINE INC Discontinued 100MG Updated Report 2022-08-10 160500
AMERGE GLAXOSMITHKLINE INC Discontinued 1MG Updated Report 2022-08-09 148427
LUPRON ABBVIE CORPORATION To be discontinued 5MG Updated Report 2022-08-08 153896
KEVZARA SANOFI-AVENTIS CANADA INC Discontinued 150MG Updated Report 2022-08-02 164491
GLUCAGON ELI LILLY CANADA INC To be discontinued 1MG New Report 2022-07-29 165759